RT Journal Article SR Electronic T1 Is the Vision of Radioligand Therapy for Prostate Cancer Becoming a Reality? An Overview of the Phase III VISION Trial and Its Importance for the Future of Theranostics JF Journal of Nuclear Medicine JO J Nucl Med FD Society of Nuclear Medicine SP 1504 OP 1506 DO 10.2967/jnumed.119.234054 VO 60 IS 11 A1 Kambiz Rahbar A1 Lisa Bodei A1 Michael J. Morris YR 2019 UL http://jnm.snmjournals.org/content/60/11/1504.abstract AB Prostate-specific membrane antigen (PSMA) is of considerable interest as a target for diagnostics and therapy of prostate cancer patients. PSMA-targeted imaging has demonstrable value in guiding the management of the clinical evolution of prostatic cancer. The use of PSMA-targeted therapy using 177Lu-labeled PSMA-617 is similarly effective and is progressing toward approval. The phase III VISION trial represents the largest well-designed and executed study of a theranostic pair. This article provides an overview of the phase III trial and delineates the different study arms and their implications in the assessment of efficacy. The VISION (phase III) trial will provide data of critical value to the field of theranostics and especially the field of prostatic cancer management.